Skip to Content
Merck
CN
  • Identification of driver genes in hepatocellular carcinoma by exome sequencing.

Identification of driver genes in hepatocellular carcinoma by exome sequencing.

Hepatology (Baltimore, Md.) (2013-06-04)
Sean P Cleary, William R Jeck, Xiaobei Zhao, Kui Chen, Sara R Selitsky, Gleb L Savich, Ting-Xu Tan, Michael C Wu, Gad Getz, Michael S Lawrence, Joel S Parker, Jinyu Li, Scott Powers, Hyeja Kim, Sandra Fischer, Maha Guindi, Anand Ghanekar, Derek Y Chiang
ABSTRACT

Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma (HCC). As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in HCC. We performed whole-exome sequencing on 87 HCCs and matched normal adjacent tissues to an average coverage of 59×. The overall mutation rate was roughly two mutations per Mb, with a median of 45 nonsynonymous mutations that altered the amino acid sequence (range, 2-381). We found recurrent mutations in several genes with high transcript levels: TP53 (18%); CTNNB1 (10%); KEAP1 (8%); C16orf62 (8%); MLL4 (7%); and RAC2 (5%). Significantly affected gene families include the nucleotide-binding domain and leucine-rich repeat-containing family, calcium channel subunits, and histone methyltransferases. In particular, the MLL family of methyltransferases for histone H3 lysine 4 were mutated in 20% of tumors. The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of HCC.